Is defective microcirculation responsible for insulin resistance?: Part 1: Microvascular dysfunction and insulin resistance are linked: Evidences from clinical observations

Microcirculation and Insulin Resistance

Volumn , Issue , 2009, Pages 119-139

  Wiernsperger, Nicolas ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Endothelial dysfunction; Insulin resistance; Metabolic syndrome; Microcirculation

Indexed keywords

EID: 70450128689     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805057410901010119     Document Type: Chapter

References (280)

1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003 Oct 8; 290(14): 1884-90.
2. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008 Sep; 31(9): 1898-904.
3. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Sr., Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007 May; 30(5): 12 19-25.
4. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995 Apr; 44(4): 369-74.
5. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabet Med 1996; 13(3 Suppl 2): S15-9.
6. Ardern CI, Janssen I. Metabolic syndrome and its association with morbidity and mortality. Appl Physiol Nutr Metab 2007 Feb; 32(1): 33-45.
7. Razzouk L, Muntner P. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr Hypertens Rep 2009 Apr; 11(2): 127-32.
8. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005 Sep; 28(9): 2289-304.
9. Raji A, Gerhard-Herman MD, Warren M, Silverman SG, Raptopoulos V, Mantzoros CS, et al. Insulin resistance and vascular dysfunction in nondiabetic Asian Indians. J Clin Endocrinol Metab 2004 Aug; 89(8): 3965-72.
10. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005 Jul 5; 112(1): 32-8.
11. Sumner AE. The relationship of body fat to metabolic disease: influence of sex and ethnicity. Gend Med 2008 Dec; 5(4): 361-71.
12. Meis SB, Schuster D, Gaillard T, Osei K. Metabolic syndrome in nondiabetic, obese, first-degree relatives of African American patients with type 2 diabetes: African American triglycerides-HDL-C and insulin resistance paradox. Ethn Dis 2006 Autumn; 16(4): 830-6.
13. Reimann M, Schutte AE, Malan NT, Schwarz PE, Benndorf RA, Schulze F, et al. Asymmetric dimethylarginine is associated with parameters of glucose metabolism in Caucasian but not in African women from South Africa. Exp Clin Endocrinol Diabetes 2007 Oct; 115(9): 600-5.
14. Garcia RG, Perez M, Maas R, Schwedhelm E, Boger RH, Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007 Nov 15; 122(2): 176-8.
15. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006 Aug; 91(8): 2906-12.
16. Mikhail N. The metabolic syndrome: insulin resistance. Curr Hypertens Rep 2009 Apr; 11(2): 156-8.
17. Onat A, Hergenc G, Turkmen S, Yazici M, Sari I, Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 2006 Apr; 55(4): 445-52.
18. Sandberg K. The metabolic syndrome: racist, sexist, or both? Gend Med 2008 Dec; 5(4): 372-3.
19. Hunt KJ, Williams K, Hazuda HP, Stern MP, Haffner SM. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann Epidemiol 2007 Nov; 17(11): 870-7.
20. Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007; 4 Suppl B: S162-77.
21. Skilton MR, Lai NT, Griffiths KA, Molyneaux LM, Yue DK, Sullivan DR, et al. Meal-related increases in vascular reactivity are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow. Am J Physiol Heart Circ Physiol 2005 Mar; 288(3): H1404-10.
22. Wendelhag I, Fagerberg B, Hulthe J, Bokemark L, Wikstrand J. Endothelium-dependent flow-mediated vasodilatation, insulin resistance and the metabolic syndrome in 60-year-old men. J Intern Med 2002 Oct; 252(4): 305-13.
23. Wright CI, Scholten HJ, Schilder JC, Elsen BM, Hanselaar W, Kroner CI, et al. Arterial stiffness, endothelial function and microcirculatory reactivity in healthy young males. Clin Physiol Funct Imaging 2008 Sep; 28(5): 299-306.
24. Wiernsperger N. Defects in microvascular haemodynamics during prediabetes: contributor or epiphenomenon? Diabetologia 2000 Nov; 43(11): 1439-48.
25. Ghiadoni L, Versari D, Giannarelli C, Faita F, Taddei S. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des 2008; 14(35): 3715-22.
26. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008 Jan; 294(1): E15-26.
27. Lott ME, Hogeman C, Herr M, Bhagat M, Kunselman A, Sinoway LI. Vasoconstrictor responses in the upper and lower limbs to increases in transmural pressure. J Appl Physiol 2009 Jan; 106(1): 302-10.
28. Proctor DN, Newcomer SC. Is there a difference in vascular reactivity of the arms and legs? Med Sci Sports Exerc 2006 Oct; 38(10): 18 19-28.
29. Turner J, Belch JJ, Khan F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med 2008 May; 18(4): 109-16.
30. Mather K. Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol Endocrinol Metab 2009 Feb; 296(2): E398-9.
31. Gray SD, Renkin EM, Mangseth G. Distribution of capillaries to fibers of different types in mixed muscle. Bibl Anat 1977(15 Pt 1): 535-8.
32. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987 Aug; 80(2): 415-24.
33. Hernandez N, Torres SH, Vera O, De Sanctis JB, Flores E. Muscle fiber composition and capillarization in relation to metabolic alterations in hypertensive men. J Med 2001; 32(1-2): 67-82.
34. Lithell H, Lindgarde F, Hellsing K, Lundqvist G, Nygaard E, Vessby B, et al. Body weight, skeletal muscle morphology, and enzyme activities in relation to fasting serum insulin concentration and glucose tolerance in 48-year-old men. Diabetes 1981 Jan; 30(1): 19-25.
35. Marin P, Andersson B, Krotkiewski M, Bjorntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994 May; 17(5): 382-6.
36. Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, et al. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006 Apr; 29(4): 895-900.
37. Nyholm B, Qu Z, Kaal A, Pedersen SB, Gravholt CH, Andersen JL, et al. Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 1997 Nov; 46(11): 1822-8.
38. Jensen CB, Storgaard H, Madsbad S, Richter EA, Vaag AA. Altered skeletal muscle fiber composition and size precede whole-body insulin resistance in young men with low birth weight. J Clin Endocrinol Metab 2007 Apr; 92(4): 1530-4.
39. Toft I, Bonaa KH, Lindal S, Jenssen T. Insulin kinetics, insulin action, and muscle morphology in lean or slightly overweight persons with impaired glucose tolerance. Metabolism 1998 Jul; 47(7): 848-54.
40. Gravholt CH, Nyholm B, Saltin B, Schmitz O, Christiansen JS. Muscle fiber composition and capillary density in Turner syndrome: evidence of increased muscle fiber size related to insulin resistance. Diabetes Care 2001 Sep; 24(9): 1668-73.
41. Cheng C, Daskalakis C, Falkner B. Capillary rarefaction in treated and untreated hypertensive subjects. Ther Adv Cardiovasc Dis 2008 Apr; 2(2): 79-88.
42. Gaster M, Staehr P, Beck-Nielsen H, Schroder HD, Handberg A. GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes 2001 Jun; 50(6): 1324-9.
43. Halseth AE, Bracy DP, Wasserman DH. Functional limitations to glucose uptake in muscles comprised of different fiber types. Am J Physiol Endocrinol Metab 2001 Jun; 280(6): E994-9.
44. Rush JW, Green HJ, Maclean DA, Code LM. Oxidative stress and nitric oxide synthase in skeletal muscles of rats with post-infarction, compensated chronic heart failure. Acta Physiol Scand 2005 Nov; 185(3): 211-8.
45. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIVinfected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007 Jan; 30(1): 113-9.
46. Cameron AJ, Zimmet PZ, Shaw JE, Alberti KG. The metabolic syndrome: in need of a global mission statement. Diabet Med 2009 Mar; 26(3): 306-9.
47. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007 Jul; 30(7): 1851-6.
48. de Zeeuw D, Bakker SJ. Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease? Nat Clin Pract Cardiovasc Med 2008 Jul; 5 Suppl 1: S10-4.
49. Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. Definitions of metabolic syndrome: Where are we now? Curr Vasc Pharmacol 2006 Jul; 4(3): 185-97.
50. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007 Mar; 4(1): 32-8.
51. Ferrannini E, Iozzo P. Is insulin resistance atherogenic? A review of the evidence. Atheroscler Suppl 2006 Aug; 7(4): 5-10.
52. Carlsson AC, Wandell PE, Halldin M, de Faire U, Hellenius ML. Is a Unified Definition of Metabolic Syndrome Needed? Comparison of Three Definitions of Metabolic Syndrome in 60-Year-Old Men and Women. Metab Syndr Relat Disord 2009 Mar 14.
53. Li WJ, Xue H, Sun K, Song XD, Wang YB, Zhen YS, et al. Cardiovascular risk and prevalence of metabolic syndrome by differing criteria. Chin Med J (Engl) 2008 Aug 20; 121(16): 1532-6.
54. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. Diabet Med 2007 May; 24(5): 464-72.
55. Yudkin JS. Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology. Diabetologia 2007 Aug; 50(8): 1576-86.
56. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007 Apr; 28(7): 857-64.
57. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005 Nov; 54(11): 3252-7.
58. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007 Apr 25; 117(2): 204-10.
59. Noto D, Barbagallo CM, Cefalu AB, Falletta A, Sapienza M, Cavera G, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008 Mar; 197(1): 147-53.
60. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005 Nov 15; 112(20): 3066-72.
61. Deveci E, Yesil M, Akinci B, Yesil S, Postaci N, Arikan E, et al. Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol 2009 Jan; 32(1): 32-6.
62. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007 Feb; 30(2): 318-24.
63. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005 Jul; 28(7): 1769-78.
64. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007 Oct; 262(4): 470-8.
65. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006 Oct; 1 19(10): 812-9.
66. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007 Jan 30; 49(4): 403-14.
67. Hoang KC, Ghandehari H, Lopez VA, Barboza MG, Wong ND. Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care 2008 Jul; 31(7): 1405-9.
68. Qiao Q, Laatikainen T, Zethelius B, Stegmayr B, Eliasson M, Jousilahti P, et al. Comparison of definitions of metabolic syndrome in relation to the risk of developing stroke and coronary heart disease in Finnish and Swedish cohorts. Stroke 2009 Feb; 40(2): 337-43.
69. Hong D, Jaron D, Buerk DG, Barbee KA. Heterogeneous response of microvascular endothelial cells to shear stress. Am J Physiol Heart Circ Physiol 2006 Jun; 290(6): H2498-508.
70. Suzuki T, Hirata K, Elkind MS, Jin Z, Rundek T, Miyake Y, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008 Aug; 156(2): 405-10.
71. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. Metabolic syndrome and incident end-stage peripheral vascular disease: a 14-year follow-up study in elderly Finns. Diabetes Care 2007 Dec; 30(12): 3099-104.
72. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007 Jun; 56(6): 1718-26.
73. Ganrot PO, Curman B, Kron B. Type 2 diabetes. Primary vascular disorder with metabolic symptoms? Med Hypotheses 1987 Sep; 24(1): 77-86.
74. Egan BM. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes 1991 Sep; 15 Suppl 2: 133-9.
75. Baron AD. Insulin and the vasculature--old actors, new roles. J Investig Med 1996 Oct; 44(8): 406-12.
76. Shoemaker JK, Bonen A. Vascular actions of insulin in health and disease. Can J Appl Physiol 1995 Jun; 20(2): 127-54.
77. Serne EH, de Jongh RT, Eringa EC, RG IJ, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007 Jul; 50(1): 204-11.
78. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 1998 Mar-Apr; 25(3-4): 175-84.
79. Kearney MT, Duncan ER, Kahn M, Wheatcroft SB. Insulin resistance and endothelial cell dysfunction: studies in mammalian models. Exp Physiol 2008 Jan; 93(1): 158-63.
80. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006 Nov-Dec; 22(6): 423-36.
81. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007 Aug; 262(2): 173-83.
82. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007 Feb; 18(1): 58-65.
83. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006 Apr 18; 113(15): 1888-904.
84. Festa A, D'Agostino R, Jr., Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004 Jun; 53(6): 1549-55.
85. Miyazaki Y, Akasaka H, Ohnishi H, Saitoh S, DeFronzo RA, Shimamoto K. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. Hypertens Res 2008 Jul; 31(7): 1357-63.
86. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997 Feb; 40(2): 238-43.
87. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999 Sep; 48(9): 1856-62.
88. Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 2007 Jan; 292(1): F423-9.
89. Title LM, Lonn E, Charbonneau F, Fung M, Mather KJ, Verma S, et al. Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vasc Med 2008 Nov; 13(4): 263-70.
90. Wong TY, Duncan BB, Golden SH, Klein R, Couper DJ, Klein BE, et al. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest Ophthalmol Vis Sci 2004 Sep; 45(9): 2949-54.
91. Kawasaki R, Tielsch JM, Wang JJ, Wong TY, Mitchell P, Tano Y, et al. The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. Br J Ophthalmol 2008 Feb; 92(2): 161-6.
92. Melikian N, Chowienczyk P, MacCarthy PA, Williams IL, Wheatcroft SB, Sherwood R, et al. Determinants of endothelial function in asymptomatic subjects with and without the metabolic syndrome. Atherosclerosis 2008 Mar; 197(1): 375-82.
93. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol 2007 Feb; 292(2): H904-11.
94. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996 Jun 1; 97(11): 2601-10.
95. de Jongh RT, Clark AD, RG IJ, Serne EH, de Vries G, Stehouwer CD. Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 2004 Jun; 47(6): 978-86.
96. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007 Aug; 22: 252-60.
97. Silva E, Genelhu, V, Tibirica, EV, Duarte, SF, Santos, LJ, Valenca, DT, Pina, RS, Caramuru, EP, Celoria, BM, Figueiredo, DP, Francischetti, EA, editor. Evaluation of the microvascular function in metabolic syndrome: relevance for the metabolic risk profile associated with obesity. Diab Vasc Dis Res; 2007.
98. Rocchini AP, Moorehead C, Katch V, Key J, Finta KM. Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 1992 Jun; 19(6 Pt 2): 615-20.
99. Sola E, Vaya A, Simo M, Hernandez-Mijares A, Morillas C, Espana F, et al. Fibrinogen, plasma viscosity and blood viscosity in obesity. Relationship with insulin resistance. Clin Hemorheol Microcirc 2007; 37(4): 309-18.
100. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004 Apr; 91(4): 683-9.
101. Frisbee JC. Obesity, insulin resistance, and microvessel density. Microcirculation 2007 Jun-Jul; 14(4-5): 289-98.
102. Wiernsperger N, Nivoit P, De Aguiar LG, Bouskela E. Microcirculation and the metabolic syndrome. Microcirculation 2007 Jun-Jul; 14(4-5): 403-38.
103. Wiernsperger N, Nivoit P, Bouskela E. Microcirculation in obesity: an unexplored domain. An Acad Bras Cienc 2007 Dec; 79(4): 617-38.
104. Kraemer-Aguiar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 2008 Dec; 57(12): 1740-6.
105. Fiuza M, Cortez-Dias N, Martins S, Belo A. Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study. Rev Port Cardiol 2008 Dec; 27(12): 1495-529.
106. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: a disease of the microcirculation? Hypertension 2006 Dec; 48(6): 1012-7.
107. Kullo IJ, Malik AR, Santos S, Ehrsam JE, Turner ST. Association of cardiovascular risk factors with microvascular and conduit artery function in hypertensive subjects. Am J Hypertens 2007 Jul; 20(7): 735-42.
108. Nazzaro P, Vulpis V, Schirosi G, Serio G, Battista L, Lucivero V, et al. Microvascular impairment is associated with insulin resistance in euglycemic mild hypertensives. Am J Hypertens 2008 Apr; 21(4): 432-7.
109. Irving RJ, Walker BR, Noon JP, Watt GC, Webb DJ, Shore AC. Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res 2002 Jan; 53(1): 271-6.
110. de Jongh RT, Serne EH, RG IJ, Stehouwer CD. Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension. J Hypertens 2007 Sep; 25(9): 1887-93.
111. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) 2008 Oct; 9(10): 987-92.
112. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003 Jun; 24(3): 302-12.
113. Macut D, Micic D, Cvijovic G, Sumarac M, Kendereski A, Zoric S, et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001; 14 Suppl 5: 1353-59; discussion 65.
114. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 Mar 13; 103(10): 1410-5.
115. Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascula dysfunction in women with polycystic ovary syndrome. Hum Reprod 2005 Nov; 20(11): 32 19-24.
116. Alexandraki K, Protogerou AD, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, et al. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens) 2006 Apr-Jun; 5(2): 126-36.
117. Ketel IJ, Stehouwer CD, Serne EH, Korsen TJ, Hompes PG, Smulders YM, et al. Obese but not normalweight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab 2008 Sep; 93(9): 3365-72.
118. Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2008 Sep 17.
119. Oral B, Mermi B, Dilek M, Alanoglu G, Sutcu R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009 Feb; 25(2): 110-6.
120. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998 Feb; 69(2): 236-41.
121. Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J 2009 Apr; 33(4): 907-14.
122. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004 Sep 15; 160(6): 521-30.
123. Bonsignore MR, Zito A. Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk. Arch Physiol Biochem 2008 Oct; 114(4): 255-60.
124. Wiernsperger N, Nivoit P, Bouskela E. Obstructive sleep apnea and insulin resistance: a role for microcirculation? Clinics 2006 Jun; 61(3): 253-66.
125. Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med Rev 2007 Jun; 11(3): 163-78.
126. Makino S, Handa H, Suzukawa K, Fujiwara M, Nakamura M, Muraoka S, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006 Jan; 64(1): 12-9.
127. Punjabi NM, Beamer BA. Alterations in Glucose Disposal in Sleep-disordered Breathing. Am J Respir Crit Care Med 2009 Feb 1; 179(3): 235-40.
128. Theorell-Haglow J, Berne C, Janson C, Lindberg E. Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. Eur Respir J 2008 May; 31(5): 1054-60.
129. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 2003 Jul; 254(1): 32-44.
130. Ramadan W, Dewasmes G, Petitjean M, Wiernsperger N, Delanaud S, Geloen A, et al. Sleep apnea is induced by a high-fat diet and reversed and prevented by metformin in non-obese rats. Obesity (Silver Spring) 2007 Jun; 15(6): 1409-18.
131. Bhattacharjee R, Kheirandish-Gozal L, Pillar G, Gozal D. Cardiovascular complications of obstructive sleep apnea syndrome: evidence from children. Prog Cardiovasc Dis 2009 Mar-Apr; 51(5): 416-33.
132. Pack AI, Gislason T. Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 2009 Mar-Apr; 51(5): 434-51.
133. Nazzaro P, Schirosi G, Clemente R, Battista L, Serio G, Boniello E, et al. Severe obstructive sleep apnoea exacerbates the microvascular impairment in very mild hypertensives. Eur J Clin Invest 2008 Oct; 38(10): 766-73.
134. Tasali E, Van Cauter E, Ehrmann DA. Polycystic Ovary Syndrome and Obstructive Sleep Apnea. Sleep Med Clin 2008 Mar; 3(1): 37-46.
135. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008 Feb 15; 5(2): 207-17.
136. Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis 2009 Mar-Apr; 51(5): 351-62.
137. Lavie L. Oxidative stress--a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis 2009 Jan-Feb; 51(4): 303-12.
138. Wolf J, Lewicka J, Narkiewicz K. Obstructive sleep apnea: an update on mechanisms and cardiovascular consequences. Nutr Metab Cardiovasc Dis 2007 Mar; 17(3): 233-40.
139. Nacher M, Serrano-Mollar A, Farre R, Panes J, Segui J, Montserrat JM. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 2007 Jan 15; 155(1): 93-6.
140. Iiyori N, Alonso LC, Li J, Sanders MH, Garcia-Ocana A, O'Doherty RM, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007 Apr 15; 175(8): 851-7.
141. Bertuglia S, Reiter RJ. Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. J Pineal Res 2009 Apr; 46(3): 307-13.
142. Wahlin Larsson B, Kadi F, Ulfberg J, Piehl Aulin K. Skeletal muscle morphology and aerobic capacity in patients with obstructive sleep apnoea syndrome. Respiration 2008; 76(1): 21-7.
143. Stal PS, Lindman R, Johansson B. Capillary supply of the soft palate muscles is reduced in long-term habitual snorers. Respiration 2009; 77(3): 303-10.
144. O'Donnell CP. Metabolic consequences of intermittent hypoxia. Adv Exp Med Biol 2007; 618: 41-9.
145. Steiropoulos P, Papanas N, Nena E, Tsara V, Fitili C, Tzouvelekis A, et al. Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: Does adherence to CPAP treatment improve glycemic control? Sleep Med 2009 Feb 20.
146. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006 Mar; 40 Suppl 1: S5-10.
147. Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr 2006 Winter; 1(1): 36-40.
148. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007 Nov; 91(6): 1125-49, ix.
149. Amarapurkar DN, Patel ND. Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis. Trop Gastroenterol 2004 Jul-Sep; 25(3): 125-9.
150. Andre P, Balkau B, Vol S, Charles MA, Eschwege E. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007 Sep; 30(9): 2355-61.
151. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009 Feb; 11(1): 50-5.
152. Montecucco F, Mach F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr Metab Immune Disord Drug Targets 2008 Dec; 8(4): 301-7.
153. Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, et al. Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci 2005 Sep-Oct; 9(5): 269-71.
154. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008 Nov; 51(11): 1947-53.
155. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 2008 Jun; 291(6): 684-92.
156. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Zgliczynski W, Jeske W. High blood pressure and hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens A 1989; 11(3): 407-25.
157. Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002 Jul; 87(7): 3174-9.
158. Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000 Oct; 53(4): 445-51.
159. Chanson P, Megnien JL, del Pino M, Coirault C, Merli I, Houdouin L, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf) 1998 Dec; 49(6): 725-31.
160. Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, et al. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine 2008 Nov 18.
161. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006 Jul; 49(7): 1661-9.
162. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 2002 Dec 18; 40(12): 2189-94.
163. Lekakis J, Papamicheal C, Stamatelopoulos K, Cimponeriu A, Voutsas A, Vemmos K, et al. Hemochromatosis associated with endothelial dysfunction: evidence for the role of iron stores in early atherogenesis. Vasc Med 1999; 4(3): 147-8.
164. Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping. Pediatr Diabetes 2004 Sep; 5(3): 126-32.
165. Messina MF, Lombardo F, Meo A, Miceli M, Wasniewska M, Valenzise M, et al. Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major. J Endocrinol Invest 2002 Jun; 25(6): 497-501.
166. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007 Dec; 5(2): 642-8.
167. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001 Oct; 80(10): 577-83.
168. Butthep P, Nuchprayoon I, Futrakul N. Endothelial injury and altered hemodynamics in thalassemia. Clin Hemorheol Microcirc 2004; 31(4): 287-93.
169. Brudevold R, Hole T, Hammerstrom J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS ONE 2008; 3(10): e3547.
170. Vari IS, Balkau B, Kettaneh A, Andre P, Tichet J, Fumeron F, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007 Jul; 30(7): 1795-801.
171. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007 Mar; 61(3): 463-72.
172. Filardi PP, Paolillo S, Marciano C, Iorio A, Losco T, Marsico F, et al. Cardiovascular effects of antiretroviral drugs: clinical review. Cardiovasc Hematol Disord Drug Targets 2008 Dec; 8(4): 238-44.
173. Shankar SS, Dube MP. Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovasc Toxicol 2004; 4(3): 261-9.
174. Dube MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008 Aug 15; 47(4): 567-74.
175. Monsuez JJ, Dufaux J, Vittecoq D, Vicaut E. Reduced reactive hyperemia in HIV-infected patients. J Acquir Immune Defic Syndr 2000 Dec 15; 25(5): 434-42.
176. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7(4): 223-42.
177. Monsuez JJ, Dufaux J, Vittecoq D, Flaud P, Vicaut E. Hemorheology in asymptomatic HIV-infected patients. Clin Hemorheol Microcirc 2000; 23(1): 59-66.
178. Dadgostar H, Holland GN, Huang X, Tufail A, Kim A, Fisher TC, et al. Hemorheologic abnormalities associated with HIV infection: in vivo assessment of retinal microvascular blood flow. Invest Ophthalmol Vis Sci 2006 Sep; 47(9): 3933-8.
179. Maggi P, Bellacosa C, Grattagliano V, Pastore G, Lapadula G. Functional impairments of microcirculation in HIV-positive patients: a laser Doppler fluxometry-based investigation. HIV Clin Trials 2008 Nov-Dec; 9(6): 428-33.
180. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001 Sep 1; 167(5): 2766-71.
181. Fernandez-Real JM, Lopez-Bermejo A, Castro A, Casamitjana R, Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. J Clin Endocrinol Metab 2006 Sep; 91(9): 3337-43.
182. Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M, Zamrazil V. Insulin sensitivity and counterregulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med 2005; 43(7): 715-20.
183. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997 Jun; 7(3): 411-4.
184. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006 Feb; 154(2): 197-212.
185. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006 Oct-Dec; 20(4): 298-301.
186. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr 2008 Jul; 13(7): 606-13.
187. Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H. Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease. Neurosci Lett 2007 May 1; 417(2): 128-31.
188. Khalil Z, Chen H, Helme RD. Mechanisms underlying the vascular activity of beta-amyloid protein fragment (beta A(4)25-35) at the level of skin microvasculature. Brain Res 1996 Oct 14; 736(1-2): 206-16.
189. Maslo C, Peraldi MN, Desenclos JC, Mougenot B, Cywiner-Golenzer C, Chatelet FP, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997 Mar; 24(3): 350-5.
190. Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ. Hemorheological mechanisms in Alzheimer's disease. Microcirculation 2007 Aug; 14(6): 627-34.
191. Guize L, Pannier B, Thomas F, Bean K, Jego B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis 2008 Sep; 101(9): 577-83.
192. Kovaite M, Petrulioniene Z, Ryliskyte L, Badariene J, Dzenkeviciute V, Cypiene A, et al. Systemic assessment of arterial wall structure and function in metabolic syndrome. Proc West Pharmacol Soc 2007; 50: 123-30.
193. Adolphe A, Cook LS, Huang X. A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. Mayo Clin Proc 2009 Mar; 84(3): 221-8.
194. Achimastos AD, Efstathiou SP, Christoforatos T, Panagiotou TN, Stergiou GS, Mountokalakis TD. Arterial stiffness: determinants and relationship to the metabolic syndrome. Angiology 2007 Feb-Mar; 58(1): 11-20.
195. Ghiadoni L, Penno G, Giannarelli C, Plantinga Y, Bernardini M, Pucci L, et al. Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension 2008 Feb; 51(2): 440-5.
196. Nam JS, Park JS, Cho MH, Jee SH, Lee HS, Ahn CW, et al. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Diabetes Res Clin Pract 2009 May; 84(2): 145-51.
197. Zhe XW, Zeng J, Tian XK, Chen W, Gu Y, Cheng LT, et al. Pulse wave velocity is associated with metabolic syndrome components in CAPD patients. Am J Nephrol 2008; 28(4): 641-6.
198. Westerbacka J, Yki-Jarvinen H. Arterial stiffness and insulin resistance. Semin Vasc Med 2002 May; 2(2): 157-64.
199. Yki-Jarvinen H, Westerbacka J. Insulin resistance, arterial stiffness and wave reflection. Adv Cardiol 2007; 44: 252-60.
200. Scuteri A, Tesauro M, Rizza S, Iantorno M, Federici M, Lauro D, et al. Endothelial function and arterial stiffness in normotensive normoglycemic first-degree relatives of diabetic patients are independent of the metabolic syndrome. Nutr Metab Cardiovasc Dis 2008 Jun; 18(5): 349-56.
201. Stern MP, Morales PA, Haffner SM, Valdez RA. Hyperdynamic circulation and the insulin resistance syndrome ("syndrome X"). Hypertension 1992 Dec; 20(6): 802-8.
202. Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, et al. Parental hyperdynamic circulation predicts insulin resistance in offspring: The Tecumseh Offspring Study. Hypertension 1999 Mar; 33(3): 769-74.
203. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999 Aug; 104(4): 447-57.
204. Sambuceti G, L'Abbate A, Marzilli M. Why should we study the coronary microcirculation? Am J Physiol Heart Circ Physiol 2000 Dec; 279(6): H2581-4.
205. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998 Mar 3; 97(8): 765-72.
206. AlZadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009 Mar 3; 53(9): 747-53.
207. Nishio K, Shigemitsu M, Kusuyama T, Fukui T, Kawamura K, Itoh S, et al. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med 2006 Apr-Jun; 7(2): 54-60.
208. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, et al. Five-year risk of developing clinical diabetes after first myocardial infarction; the FINAMI study. Diabet Med 2005 Oct; 22(10): 1334-7.
209. Thomas DP, Hudlicka O. Arteriolar reactivity and capillarization in chronically stimulated rat limb skeletal muscle post-MI. J Appl Physiol 1999 Dec; 87(6): 2259-65.
210. Richardson TE, Kindig CA, Musch TI, Poole DC. Effects of chronic heart failure on skeletal muscle capillary hemodynamics at rest and during contractions. J Appl Physiol 2003 Sep; 95(3): 1055-62.
211. Xu L, Poole DC, Musch TI. Effect of heart failure on muscle capillary geometry: implications for 02 exchange. Med Sci Sports Exerc 1998 Aug; 30(8): 1230-7.
212. Nusz DJ, White DC, Dai Q, Pippen AM, Thompson MA, Walton GB, et al. Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. Am J Physiol Heart Circ Physiol 2003 Oct; 285(4): H1554-62.
213. Houghton AR, Harrison M, Perry AJ, Evans AJ, Cowley AJ. Endogenous insulin and insulin sensitivity. An important determinant of skeletal muscle blood flow in chronic heart failure? Eur Heart J 1998 Mar; 19(3): 476-80.
214. Ivey FM, Ryan AS, Hafer-Macko CE, Garrity BM, Sorkin JD, Goldberg AP, et al. High prevalence of abnormal glucose metabolism and poor sensitivity of fasting plasma glucose in the chronic phase of stroke. Cerebrovasc Dis 2006; 22(5-6): 368-71.
215. Prior SJ, McKenzie MJ, Joseph LJ, Ivey FM, Macko RF, Hafer-Macko CE, et al. Reduced skeletal muscle capillarization and glucose intolerance. Microcirculation 2009 Apr; 16(3): 203-12.
216. Erdem H, Dinc A, Pay S, Simsek I, Turan M. Peripheral insulin resistance in patients with Behcet's disease. J Eur Acad Dermatol Venereol 2006 Apr; 20(4): 391-5.
217. Pasqui AL, Pastorelli M, Puccetti L, Beerman U, Biagi F, Camarri A, et al. Microvascular assessment in Behcet disease: videocapillaroscopic study. Int J Tissue React 2003; 25(3): 105-15.
218. Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A, et al. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 2009 Feb; 36(2): 295-7.
219. Cacciapaglia F, Zardi E, Coppolino G, Buzzulini F, Margiotta D, Arcarese L, et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus 2009; 18(3): 249-56.
220. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005 Dec; 20(6): 1029-33.
221. Lembo G, Iaccarino G, Vecchione C, Rendina V, Trimarco B. Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension 1995 Aug; 26(2): 290-3.
222. Straczkowski M, Kowalska I, Stepien A, Dzienis-Straczkowska S, Szelachowska M, Kinalska I, et al. Insulin resistance in the first-degree relatives of persons with type 2 diabetes. Med Sci Monit 2003 May; 9(5): CR186-90.
223. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, et al. Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol 2006 Jun 20; 47(12): 2456-61.
224. Ekelund U, Anderssen S, Andersen LB, Riddoch CJ, Sardinha LB, Luan J, et al. Prevalence and correlates of the metabolic syndrome in a population-based sample of European youth. Am J Clin Nutr 2009 Jan; 89(1): 90-6.
225. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000 Apr 18; 101(15): 1780-4.
226. Jorneskog G, Kalani M, Kuhl J, Bavenholm P, Katz A, Allerstrand G, et al. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care 2005 Jun; 28(6): 1495-7.
227. McSorley PT, Bell PM, Young IS, Atkinson AB, Sheridan B, Fee JP, et al. Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with Type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial. Diabet Med 2005 Jun; 22(6): 703-10.
228. Sonne MP, Hojbjerre L, Alibegovic AA, Vaag A, Stallknecht B, Dela F. Impaired endothelial function and insulin action in first-degree relatives of patients with type 2 diabetes mellitus. Metabolism 2009 Jan; 58(1): 93-101.
229. Lee BC, Shore AC, Humphreys JM, Lowe GD, Rumley A, Clark PM, et al. Skin microvascular vasodilatory capacity in offspring of two parents with Type 2 diabetes. Diabet Med 2001 Jul; 18(7): 541-5.
230. Gurlek A, Bayraktar M, Kirazli S. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 2000 Jan; 23(1): 88-92.
231. Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamaki J, Punnonen K, Kainulainen S, et al. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis 2008 Mar; 197(1): 271-7.
232. Tesauro M, Rizza S, Iantorno M, Campia U, Cardillo C, Lauro D, et al. Vascular, metabolic, and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. Metabolism 2007 Mar; 56(3): 413-9.
233. Maumus S, Marie B, Siest G, Visvikis-Siest S. A prospective study on the prevalence of metabolic syndrome among healthy french families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care 2005 Mar; 28(3): 675-82.
234. Maltezos E, Papazoglou D, Exiara T, Papazoglou L, Karathanasis E, Christakidis D, et al. Tumour necrosis factor-alpha levels in non-diabetic offspring of patients with type 2 diabetes mellitus. J Int Med Res 2002 Nov-Dec; 30(6): 576-83.
235. Hunt KJ, Heiss G, Sholinsky PD, Province MA. Familial history of metabolic disorders and the multiple metabolic syndrome: the NHLBI family heart study. Genet Epidemiol 2000 Dec; 19(4): 395-409.
236. Lazarin MA, Bennini JR, Pereira CL, Astiarraga BD, Ferrannini E, Muscelli E. Normal insulin sensitivity in lean offspring of obese parents. Obes Res 2004 Apr; 12(4): 621-6.
237. Chen HS, Hwu CM, Kwok CF, Shih KC, Hsiao LC, Lee SH, et al. Insulin sensitivity in normotensive offspring of hypertensive parents. Horm Metab Res 2000 Mar; 32(3): 110-4.
238. Dunkley AJ, Taub NA, Davies MJ, Stone MA, Khunti K. Is having a family history of type 2 diabetes or cardiovascular disease a predictive factor for metabolic syndrome? Prim Care Diabetes 2009 Feb; 3(1): 49-56.
239. Ohtoshi K, Yamasaki Y, Gorogawa S, Hayaishi-Okano R, Node K, Matsuhisa M, et al. Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance. Diabetologia 2002 Nov; 45(11): 1594-601.
240. Rizza S, Tesauro M, Cardellini M, Menghini R, Bellia A, Marini MA, et al. Insulin resistance and increased intimal medial thickness in glucose tolerant offspring of type 2 diabetic subjects carrying the D298D genotype of endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2006 Feb; 26(2): 431-2.
241. Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhisa M, et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 2005 May 27; 331(1): 347-50.
242. Parry DJ, Grant PJ, Scott DJ. Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication. Br J Surg 2006 Mar; 93(3): 315-24.
243. Anderwald C, Pfeiler G, Nowotny P, Anderwald-Stadler M, Krebs M, Bischof MG, et al. Glucose turnover and intima media thickness of internal carotid artery in type 2 diabetes offspring. Eur J Clin Invest 2008 Apr; 38(4): 227-37.
244. Lee JW, Lee DC, Im JA, Shim JY, Kim SM, Lee HR. Insulin resistance is associated with arterial stiffness independent of obesity in male adolescents. Hypertens Res 2007 Jan; 30(1): 5-11.
245. Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E, et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation 2005 Dec 13; 112(24): 3722-8.
246. Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Gialernios TP, Spanos PG, et al. Arterial hypertension parental burden affects arterial stiffness and wave reflection to the aorta in young offsprings. Int J Cardiol 2009 Jan 26.
247. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993 Feb 13; 306(6875): 422-6.
248. Vaag A. Low birth weight and early weight gain in the metabolic syndrome: consequences for infant nutrition. Int J Gynaecol Obstet 2009 Mar; 104 Suppl 1: S32-4.
249. Fagerberg B, Bondjers L, Nilsson P. Low birth weight in combination with catch-up growth predicts the occurrence of the metabolic syndrome in men at late middle age: the Atherosclerosis and Insulin Resistance study. J Intern Med 2004 Sep; 256(3): 254-9.
250. Lapidus L, Andersson SW, Bengtsson C, Bjorkelund C, Rossander-Hulthen L, Lissner L. Weight and length at birth and their relationship to diabetes incidence and all-cause mortality--a 32-year follow-up of the population study of women in Gothenburg, Sweden. Prim Care Diabetes 2008 Sep; 2(3): 127-33.
251. Hediger ML, Overpeck MD, Kuczmarski RJ, McGlynn A, Maurer KR, Davis WW. Muscularity and fatness of infants and young children born small-or large-for-gestational-age. Pediatrics 1998 Nov; 102(5): E60.
252. Reinehr T, Kleber M, Toschke AM. Small for gestational age status is associated with metabolic syndrome in overweight children. Eur J Endocrinol 2009 Apr; 160(4): 579-84.
253. Martin H, Hu J, Gennser G, Norman M. Impaired endothelial function and increased carotid stiffness in 9-year-old children with low birthweight. Circulation 2000 Nov 28; 102(22): 2739-44.
254. Smith GD, Sterne J, Tynelius P, Lawlor DA, Rasmussen F. Birth weight of offspring and subsequent cardiovascular mortality of the parents. Epidemiology 2005 Jul; 16(4): 563-9.
255. Goh KL, Shore AC, Quinn M, Tooke JE. Impaired microvascular vasodilatory function in 3-month-old infants of low birth weight. Diabetes Care 2001 Jun; 24(6): 1102-7.
256. Martin H, Gazelius B, Norman M. Impaired acetylcholine-induced vascular relaxation in low birth weight infants: implications for adult hypertension? Pediatr Res 2000 Apr; 47(4 Pt 1): 457-62.
257. Albareda M, Caballero A, Badell G, Rodriguez-Espinosa J, Ordonez-Llanos J, de Leiva A, et al. Metabolic syndrome at follow-up in women with and without gestational diabetes mellitus in index pregnancy. Metabolism 2005 Aug; 54(8): 1115-21.
258. Byberg L, McKeigue PM, Zethelius B, Lithell HO. Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia 2000 Jan; 43(1): 54-60.
259. Lauenborg J, Mathiesen E, Hansen T, Glumer C, Jorgensen T, Borch-Johnsen K, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005 Jul; 90(7): 4004-10.
260. Cheung NW, Helmink D. Gestational diabetes: the significance of persistent fasting hyperglycemia for the subsequent development of diabetes mellitus. J Diabetes Complications 2006 Jan-Feb; 20(1): 21-5.
261. Banerjee M, Cruickshank JK. Pregnancy as the prodrome to vascular dysfunction and cardiovascular risk. Nat Clin Pract Cardiovasc Med 2006 Nov; 3(11): 596-603.
262. Damm P. Future risk of diabetes in mother and child after gestational diabetes mellitus. Int J Gynaecol Obstet 2009 Mar; 104 Suppl 1: S25-6.
263. Pleiner J, Mittermayer F, Langenberger H, Winzer C, Schaller G, Pacini G, et al. Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. Wien Klin Wochenschr 2007; 1 19(15-16): 483-9.
264. Seghieri G, Anichini R, De Bellis A, Alviggi L, Franconi F, Breschi MC. Relationship between gestational diabetes mellitus and low maternal birth weight. Diabetes Care 2002 Oct; 25(10): 1761-5.
265. Hu J, Norman M, Wallensteen M, Gennser G. Increased large arterial stiffness and impaired acetylcholine induced skin vasodilatation in women with previous gestational diabetes mellitus. Br J Obstet Gynaecol 1998 Dec; 105(12): 1279-87.
266. Middlebrooke AR, Armstrong N, Welsman JR, Shore AC, Clark P, MacLeod KM. Does aerobic fitness influence microvascular function in healthy adults at risk of developing Type 2 diabetes? Diabet Med 2005 Apr; 22(4): 483-9.
267. Hannemann MM, Liddell WG, Shore AC, Clark PM, Tooke JE. Vascular function in women with previous gestational diabetes mellitus. J Vasc Res 2002 Jul-Aug; 39(4): 311-9.
268. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005 Jul; 90(7): 3983-8.
269. Mittermayer F, Kautzky-Willer A, Winzer C, Krzyzanowska K, Prikoszovich T, Demehri S, et al. Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med 2007 Apr; 261(4): 392-8.
270. Akinci B, Celtik A, Yener S, Yesil S. Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertil Steril 2009 Jan 13.
271. Isezuo SA, Ekele BA. Comparison of metabolic syndrome variables among pregnant women with and without eclampsia. J Natl Med Assoc 2008 Sep; 100(9): 1059-62.
272. Soonthornpun K, Soonthornpun S, Wannaro P, Setasuban W, Thamprasit A. Insulin resistance in women with a history of severe pre-eclampsia. J Obstet Gynaecol Res 2009 Feb; 35(1): 55-9.
273. Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007 Oct; 334(4): 291-5.
274. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004 Aug; 175(2): 189-202.
275. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004 Dec; 89(12): 6239-43.
276. Blaauw J, Graaff R, van Pampus MG, van Doormaal JJ, Smit AJ, Rakhorst G, et al. Abnormal endotheliumdependent microvascular reactivity in recently preeclamptic women. Obstet Gynecol 2005 Mar; 105(3): 626-32.
277. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm M, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol 2005 Apr; 25(4): 809-14.
278. Suvorava T, Lauer N, Kojda G. Physical inactivity causes endothelial dysfunction in healthy young mice. J Am Coll Cardiol 2004 Sep 15; 44(6): 1320-7.
279. Hamburg NM, McMackin CJ, Huang AL, Shenouda SM, Widlansky ME, Schulz E, et al. Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers. Arterioscler Thromb Vasc Biol 2007 Dec; 27(12): 2650-6.
280. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999 Feb 23; 99(7): 896-902.